全文获取类型
收费全文 | 8416篇 |
免费 | 848篇 |
国内免费 | 25篇 |
专业分类
耳鼻咽喉 | 76篇 |
儿科学 | 201篇 |
妇产科学 | 168篇 |
基础医学 | 1326篇 |
口腔科学 | 171篇 |
临床医学 | 919篇 |
内科学 | 1926篇 |
皮肤病学 | 115篇 |
神经病学 | 727篇 |
特种医学 | 238篇 |
外科学 | 1177篇 |
综合类 | 155篇 |
一般理论 | 7篇 |
预防医学 | 844篇 |
眼科学 | 85篇 |
药学 | 646篇 |
中国医学 | 4篇 |
肿瘤学 | 504篇 |
出版年
2021年 | 112篇 |
2019年 | 108篇 |
2018年 | 114篇 |
2016年 | 75篇 |
2015年 | 108篇 |
2014年 | 154篇 |
2013年 | 214篇 |
2012年 | 326篇 |
2011年 | 389篇 |
2010年 | 192篇 |
2009年 | 181篇 |
2008年 | 315篇 |
2007年 | 294篇 |
2006年 | 313篇 |
2005年 | 340篇 |
2004年 | 308篇 |
2003年 | 298篇 |
2002年 | 267篇 |
2001年 | 299篇 |
2000年 | 280篇 |
1999年 | 253篇 |
1998年 | 132篇 |
1997年 | 79篇 |
1996年 | 90篇 |
1995年 | 80篇 |
1994年 | 83篇 |
1993年 | 76篇 |
1992年 | 228篇 |
1991年 | 217篇 |
1990年 | 215篇 |
1989年 | 184篇 |
1988年 | 182篇 |
1987年 | 178篇 |
1986年 | 202篇 |
1985年 | 180篇 |
1984年 | 137篇 |
1983年 | 151篇 |
1982年 | 99篇 |
1981年 | 98篇 |
1980年 | 75篇 |
1979年 | 144篇 |
1978年 | 135篇 |
1977年 | 106篇 |
1976年 | 108篇 |
1975年 | 99篇 |
1974年 | 118篇 |
1973年 | 107篇 |
1970年 | 78篇 |
1969年 | 74篇 |
1968年 | 73篇 |
排序方式: 共有9289条查询结果,搜索用时 125 毫秒
1.
2.
Nicolas Mottet Roderick C.N. van den Bergh Erik Briers Thomas Van den Broeck Marcus G. Cumberbatch Maria De Santis Stefano Fanti Nicola Fossati Giorgio Gandaglia Silke Gillessen Nikos Grivas Jeremy Grummet Ann M. Henry Theodorus H. van der Kwast Thomas B. Lam Michael Lardas Matthew Liew Malcolm D. Mason Philip Cornford 《European urology》2021,79(2):243-262
ObjectiveTo present a summary of the 2020 version of the European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG) guidelines on screening, diagnosis, and local treatment of clinically localised prostate cancer (PCa).Evidence acquisitionThe panel performed a literature review of new data, covering the time frame between 2016 and 2020. The guidelines were updated and a strength rating for each recommendation was added based on a systematic review of the evidence.Evidence synthesisA risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around 40 yr of age. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is performed, a combination of targeted and systematic biopsies must be offered. There is currently no place for the routine use of tissue-based biomarkers. Whilst prostate-specific membrane antigen positron emission tomography computed tomography is the most sensitive staging procedure, the lack of outcome benefit remains a major limitation. Active surveillance (AS) should always be discussed with low-risk patients, as well as with selected intermediate-risk patients with favourable International Society of Urological Pathology (ISUP) 2 lesions. Local therapies are addressed, as well as the AS journey and the management of persistent prostate-specific antigen after surgery. A strong recommendation to consider moderate hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term hormonal treatment.ConclusionsThe evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. The 2020 EAU-EANM-ESTRO-ESUR-SIOG guidelines on PCa summarise the most recent findings and advice for their use in clinical practice. These PCa guidelines reflect the multidisciplinary nature of PCa management.Patient summaryUpdated prostate cancer guidelines are presented, addressing screening, diagnosis, and local treatment with curative intent. These guidelines rely on the available scientific evidence, and new insights will need to be considered and included on a regular basis. In some cases, the supporting evidence for new treatment options is not yet strong enough to provide a recommendation, which is why continuous updating is important. Patients must be fully informed of all relevant options and, together with their treating physicians, decide on the most optimal management for them. 相似文献
3.
4.
V. Jenkins I. Solis-Trapala H. Payne M. Mason L. Fallowfield S. May L. Matthews S. Catt 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):99-107
Aims
Delaying progression, ameliorating symptoms and maintaining quality of life (QoL) are primary aims of treatment for metastatic castrate-resistant prostate cancer (mCRPC). Real-world rather than clinical trial data about symptoms and side-effects are sparse. In EXTREQOL, patients' QoL, pain and information needs were recorded during treatment.Material and methods
Men with mCRPC from 20 UK cancer centres starting various systemic mCRPC treatments completed QoL, pain and information needs questionnaires at baseline, 3 and 6 months.Results
In total, 132 patients were recruited. Overall QoL declined significantly by 6 months (Functional Assessment of Cancer Therapy-Prostate [FACT-P] mean = –3.89, 95% confidence interval –6.7 to –1.05, P = 0.007; Trial Outcome Index [TOI] analysis mean = –3.10, 95% confidence interval –5.34 to –0.83, P = 0.007). Those who came off novel therapy and remained on luteinising hormone-releasing hormone agonist therapy alone had worse scores than patients receiving concomitant chemotherapy (Prostate Concerns Subscale mean difference = –4.45, 95% confidence interval –7.06 to –1.83, P = 0.001; TOI mean difference = –5.62, 95% confidence interval –10.97 to –0.26, P = 0.040). At 3 and 6 months, men who reported pain at baseline improved (43%, 40%), but for others pain levels remained the same (45%, 42%) or worsened (13%, 18%). Information regarding supportive care was lacking throughout the period of time on the study.Conclusion
Most mCRPC treated patients experience reduced QoL and inadequate pain control. More help with pain management and better information provision regarding supportive care is warranted. 相似文献5.
6.
Brittany M. Lewno-Dumdie Benjamin A. Mason Daniel B. Hajovsky Ethan F. Villeneuve 《School mental health》2020,12(1):1-21
School climate is a broad, multi-dimensional construct that represents the quality and character of school life. Although many student-reported measures of school climate are available, less is known about the specific dimensions assessed by various measures. Using three comprehensive models of school climate as a guide, a systematic literature review of school climate measurement tools was conducted with two main questions. First, which dimensions are identified and measured in published studies of student-reported school climate? Second, what overlap in studies of student-reported school climate measures exist with the model dimensions? Results from the review of 18 school climate measures largely supported five dimensions (safety, relationships, teaching and learning, institutional environment, and school improvement processes) with at least three dimensions present within all reviewed measures. The discussion elaborates on the dimensions and sub-dimensions assessed in these tools, implications for failing to measure the sub-dimension of respect for diversity, and a new sub-dimension titled academic orientation that emerged from overlap in measurement tools. 相似文献
7.
8.
9.
ABSTRACTA monocausal bacteriological understanding of infectious disease orients tuberculosis control efforts towards antimicrobial interventions. A bias towards technological solutions can leave multistranded public health and social interventions largely neglected. In the context of globalising biomedical approaches to infectious disease control, this ethnography-inspired review article reflects upon the implementation of rapid diagnostic technology in low- and middle-income countries. Fieldwork observations in Vietnam provided a stimulus for a critical review of the global rollout of tuberculosis diagnostic technology. To address local needs in tuberculosis control, health managers in resource-poor settings are readily cooperating with international donors to deploy novel diagnostic technologies throughout national tuberculosis programme facilities. Increasing investment in new diagnostic technologies is predicated on the supposition that these interventions will ameliorate disease outcomes. However, suboptimal treatment control persists even when accurate diagnostic technologies are available, suggesting that promotion of singular technological solutions can distract from addressing systemic change, without which disease susceptibility, propagation of infection, detection gaps, diagnostic delays, and treatment shortfalls persist. 相似文献
10.